STRO-001 Gets Orphan Drug Designation for Mutiple Myeloma

Share this content:
STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74
STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74

Sutro Biopharma announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for STRO-001 for the treatment of multiple myeloma. 

STRO-001 targets CD74, which is a protein highly expressed in B-cell malignancies like multiple myeloma. This potential first-in-class antibody drug conjugate (ADC) was developed with the Company's proprietary cell-free protein synthesis and site-specific conjugation platform called XpressCF+. The technology allows for the manufacturing of a highly optimized single molecular species within the product instead of the usual mixture of imprecisely conjugated antibodies that make up an ADC product designed by conventional cell-based platforms. 

Continue Reading Below

STRO-001 is being evaluated in a Phase 1 trial that includes separate dose escalation cohorts for multiple myeloma and B-cell lymphoma.

For more information visit Sutrobio.com.

Share this content:
You must be a registered member of Hematology Advisor to post a comment.

SIGN UP FOR FREE E-NEWSLETTERS